share_log

CORRESP: CORRESP

CORRESP: CORRESP

CORRESP：信函
美股sec公告 ·  04/13 01:23
牛牛AI助手已提取核心信息
Apollomics Inc., a biopharmaceutical company, has responded to a comment from the SEC regarding its operations in China. The SEC's Division of Corporation Finance had requested clarification on the extent of Apollomics' operations in China, citing the need for specific disclosures about the risks associated with China-based companies. In a letter dated April 12, 2024, Apollomics clarified that it does not conduct the majority of its operations in China, stating that it is a Cayman Islands holding company with its business headquarters and management team based in California, USA. The company conducts most of its research and development efforts outside of China, with less than 20% of these activities taking place in Hong Kong and mainland China through its subsidiaries. Apollomics also highlighted that the majority of its cash and expenditures are held and incurred outside of China. This response follows the SEC's guidance on China-specific disclosures and addresses issues previously raised in a December 2021 letter.
Apollomics Inc., a biopharmaceutical company, has responded to a comment from the SEC regarding its operations in China. The SEC's Division of Corporation Finance had requested clarification on the extent of Apollomics' operations in China, citing the need for specific disclosures about the risks associated with China-based companies. In a letter dated April 12, 2024, Apollomics clarified that it does not conduct the majority of its operations in China, stating that it is a Cayman Islands holding company with its business headquarters and management team based in California, USA. The company conducts most of its research and development efforts outside of China, with less than 20% of these activities taking place in Hong Kong and mainland China through its subsidiaries. Apollomics also highlighted that the majority of its cash and expenditures are held and incurred outside of China. This response follows the SEC's guidance on China-specific disclosures and addresses issues previously raised in a December 2021 letter.
生物制药公司Apollomics Inc. 对美国证券交易委员会关于其在中国业务的评论做出了回应。美国证券交易委员会公司财务部要求澄清Apollomics在中国的业务范围，理由是需要具体披露与中国公司相关的风险。在2024年4月12日的一封信中，Apollomics澄清说，其大部分业务并不在中国进行，称其是一家开曼群岛控股公司，其业务总部和管理团队位于美国加利福尼亚州。该公司的大部分研发工作都在中国境外进行，其中只有不到20％的活动是通过其子公司在香港和中国大陆进行的。Apollomics还强调，其大部分现金和支出都是在中国境外持有和发生的。该回应遵循美国证券交易委员会关于中国特定披露的指导方针，并解决了先前在2021年12月的信函中提出的问题。
生物制药公司Apollomics Inc. 对美国证券交易委员会关于其在中国业务的评论做出了回应。美国证券交易委员会公司财务部要求澄清Apollomics在中国的业务范围，理由是需要具体披露与中国公司相关的风险。在2024年4月12日的一封信中，Apollomics澄清说，其大部分业务并不在中国进行，称其是一家开曼群岛控股公司，其业务总部和管理团队位于美国加利福尼亚州。该公司的大部分研发工作都在中国境外进行，其中只有不到20％的活动是通过其子公司在香港和中国大陆进行的。Apollomics还强调，其大部分现金和支出都是在中国境外持有和发生的。该回应遵循美国证券交易委员会关于中国特定披露的指导方针，并解决了先前在2021年12月的信函中提出的问题。
有用
没用

该公告为独立文件：

独立文件1

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成，只对中国内地以外的地区提供。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。